Business Ethics Quarterly:1-28 (forthcoming)
Authors |
|
Abstract |
The rise of liberal market economies, propagated by neoliberal free market thought, has created a vacant responsibility for public interests in the market order of society. This development has been critiqued by Catholic social teaching, forcefully arguing that governments and businesses should be directed to the common good. In this debate, no attention has yet been given to the Reformational tradition and its principle of sphere sovereignty, which provides guidelines on the responsibilities of governments and companies for the public interest of society. This article analyzes the differences and similarities between CST and the Reformational philosophy in their critiques of the neoliberal free market perspective of Hayek. We apply the three perspectives to the case of orphan drugs in the pharmaceutical industry and show that CST and the Reformational philosophy offer valuable insights in correction to Hayek’s views on the responsibilities of governments and companies for public health interests.
|
Keywords | No keywords specified (fix it) |
Categories | (categorize this paper) |
DOI | 10.1017/beq.2022.9 |
Options |
![]() ![]() ![]() ![]() |
Download options
References found in this work BETA
Integrating Personalism Into Virtue-Based Business Ethics: The Personalist and the Common Good Principles.Domènec Melé - 2009 - Journal of Business Ethics 88 (1):227-244.
View all 26 references / Add more references
Citations of this work BETA
No citations found.
Similar books and articles
The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge: Deconstructing the Redefinition of Carcinogens in Pharmaceuticals.Rachel Ballinger & John Abraham - 2012 - Science, Technology, and Human Values 37 (5):443-477.
Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda.Paul D. Jorgensen - 2013 - Journal of Law, Medicine and Ethics 41 (3):561-570.
Common Health Policy Interests and the Shaping of Global Pharmaceutical Policies.Meri Koivusalo - 2010 - Ethics and International Affairs 24 (4):395-414.
Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry.Howard Brody - 2007 - Rowman & Littlefield Publishers.
Five Un-Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Understanding Physician-Pharmaceutical Industry Interactions: A Concise Guide.Shaili Jain - 2007 - Cambridge University Press.
The Promise of Pharmacogenetics: Assessing the Prospects for Disease and Patient Stratification.Andrew Smart & Paul Martin - 2006 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 37 (3):583-601.
How Pharmaceutical Industry Employees Manage Competing Commitments in the Face of Public Criticism.Wendy Lipworth, Kathleen Montgomery & Miles Little - 2013 - Journal of Bioethical Inquiry 10 (3):355-367.
Pharmaceutical Knowledge Governance: A Human Rights Perspective.Trudo Lemmens - 2013 - Journal of Law, Medicine and Ethics 41 (1):163-184.
Restoring a Reputation: Invoking the UNESCO Universal Declaration on Bioethics and Human Rights to Bear on Pharmaceutical Pricing.Daniel J. Hurst - 2017 - Medicine, Health Care and Philosophy 20 (1):105-117.
The Just Price, Exploitation, and Prescription Drugs: Why Free Marketeers Should Object to Profiteering by the Pharmaceutical Industry.Mark R. Reiff - 2019 - Review of Social Economy 77:1-36.
Moral Psychology and the Intuition That Pharmaceutical Companies Have a ‘Special’ Obligation to Society.James M. Huebner - 2014 - Journal of Buisness Ethics (3):1-10.
The Corporate Social Responsibility of Pharmaceutical Product Recalls: An Empirical Examination of U.S. And U.K. Markets. [REVIEW]Eng Tuck Cheah, Wen Li Chan & Corinne Lin Lin Chieng - 2007 - Journal of Business Ethics 76 (4):427-449.
Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health.Marc-André Gagnon - 2013 - Journal of Law, Medicine and Ethics 41 (3):571-580.
Analytics
Added to PP index
2022-06-26
Total views
1 ( #1,551,851 of 2,517,999 )
Recent downloads (6 months)
1 ( #409,045 of 2,517,999 )
2022-06-26
Total views
1 ( #1,551,851 of 2,517,999 )
Recent downloads (6 months)
1 ( #409,045 of 2,517,999 )
How can I increase my downloads?
Downloads
Sorry, there are not enough data points to plot this chart.
Sorry, there are not enough data points to plot this chart.